ByTrending Posts
Can Labcorp’s AI-Powered Test Finder Redefine Diagnostic Efficiency…
Key Highlights Expansion Into Clinical WorkflowsLabcorp (NYSE: LH) announced the integration of its AI-driven Test Finder into Labcorp…
Can Ambience Healthcare’s $243M Series C Push the…
Key Highlights Record Funding and Unicorn StatusAmbience Healthcare, founded in 2020 in San Francisco, announced a $243 million…
How Is Roche’s Expansive 2025 Pipeline and Innovative…
Key Highlights: Broad and Deep Pharmaceutical Pipeline ExpansionSince mid-2023, Roche has significantly enhanced its clinical pipeline, adding 24…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a…
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D…
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a global exclusive licensing…
Can GSK’s Gepotidacin Priority FDA Review and Strategic…
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite…
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R…
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug…
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
Trending Posts
Latest Stories
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding AI-Driven Precision Oncology Strategy
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after…
Gallery
